CN114225100A - Porphyridium-based liquid dressing and preparation method thereof - Google Patents
Porphyridium-based liquid dressing and preparation method thereof Download PDFInfo
- Publication number
- CN114225100A CN114225100A CN202111580252.2A CN202111580252A CN114225100A CN 114225100 A CN114225100 A CN 114225100A CN 202111580252 A CN202111580252 A CN 202111580252A CN 114225100 A CN114225100 A CN 114225100A
- Authority
- CN
- China
- Prior art keywords
- porphyridium
- parts
- liquid dressing
- phycobiliprotein
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 77
- 241000206618 Porphyridium Species 0.000 title claims description 83
- 238000002360 preparation method Methods 0.000 title abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 150000004676 glycans Chemical class 0.000 claims abstract description 34
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 34
- 239000005017 polysaccharide Substances 0.000 claims abstract description 34
- 108060006184 phycobiliprotein Proteins 0.000 claims abstract description 33
- 239000008367 deionised water Substances 0.000 claims abstract description 30
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 30
- 150000002301 glucosamine derivatives Chemical class 0.000 claims abstract description 27
- 239000011259 mixed solution Substances 0.000 claims description 32
- 238000003756 stirring Methods 0.000 claims description 30
- 230000001954 sterilising effect Effects 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 5
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 5
- 229960002442 glucosamine Drugs 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 abstract description 19
- 208000027418 Wounds and injury Diseases 0.000 abstract description 19
- 230000029663 wound healing Effects 0.000 abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 241000195493 Cryptophyta Species 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 2
- 241000206609 Porphyra Species 0.000 abstract 6
- 230000035876 healing Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 230000003385 bacteriostatic effect Effects 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 231100000241 scar Toxicity 0.000 description 7
- 238000005406 washing Methods 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 4
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 4
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 4
- 229960005323 phenoxyethanol Drugs 0.000 description 4
- 230000037387 scars Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010039509 Scab Diseases 0.000 description 3
- 206010070835 Skin sensitisation Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 231100000370 skin sensitisation Toxicity 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- BOEATSOZMRMDAA-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylsulfanyl]-n-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide Chemical group C1=CC(F)=CC=C1CSCC(=O)NC(S1)=NC2=C1CCCC2 BOEATSOZMRMDAA-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- -1 other auxiliaries Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/408—Virucides, spermicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于创面护理领域，具体涉及一种基于紫球藻的液体敷料及其制备方法，按质量份数计含如下组分：氨基葡萄糖衍生物0.5～10份、紫球藻多糖0.1～1份、紫球藻藻胆蛋白0.01～0.1份、余量为去离子水，总量为100份，其中紫球藻多糖、紫球藻藻胆蛋白及氨基葡萄糖衍生物由紫球藻藻液进行分离、纯化获得。所述液体敷料的理化及安全性符合相关标准，经验证具有抑菌性及促进伤口愈合的性能。且该液体敷料的制备方法简单，具有成分天然安全、成膜性能好、肤感舒适的特点，适于产业化应用。The invention belongs to the field of wound care, and in particular relates to a liquid dressing based on Porphyra algae and a preparation method thereof, comprising the following components in parts by mass: 0.5-10 parts of glucosamine derivatives, 0.1-1 part of Porphyra polysaccharide , 0.01-0.1 part of Porphyra phycobiliprotein, the balance is deionized water, the total amount is 100 parts, wherein Porphyra polysaccharide, Porphyra phycobiliprotein and glucosamine derivatives are separated from Porphyra algae liquid , purified. The physicochemical and safety properties of the liquid dressing meet relevant standards, and have been verified to have antibacterial properties and the performance of promoting wound healing. In addition, the preparation method of the liquid dressing is simple, and has the characteristics of natural and safe ingredients, good film-forming performance and comfortable skin feeling, and is suitable for industrial application.
Description
Technical Field
The invention relates to the field of wound surface nursing, in particular to a liquid dressing and a preparation method thereof.
Background
The skin is the largest organ of human body area, and has the functions of organically isolating human body from external environment, regulating the balance of water and electrolyte of human body, resisting the invasion of foreign matters, bacteria, viruses and the like, preventing mechanical damage and resisting the damage of ultraviolet irradiation to human body. Superficial skin injuries including abrasions, scratches, scalds, burns and the like are common. The traditional wound care products such as band-aid/gauze have the defects of strong foreign body sensation, easy adhesion with wound, easy shedding after being wetted, easy infection, obvious scar remaining after healing due to long healing period and the like.
The theory of moist healing starting in the 60's last century indicates that a moist environment can increase the rate of migration of epidermal cells, resulting in a shorter time for wound healing than would occur in a dry environment. The dressing can replace damaged skin to play a temporary barrier role in the process of wound healing, and infection of the wound can be avoided or controlled. In addition, the moist environment can promote the combination of cell growth factors and receptors, which is favorable for maintaining the activity of wound cells and promoting the healing of the wound. Based on the theory of wet healing, liquid dressings for superficial skin lesions have become a hotspot for research in recent years. It is necessary to develop a liquid dressing which has natural and safe components, comfortable skin feeling, lower cost and simple preparation method.
The conventional liquid dressing is relatively complex in components, generally needs to be added with film-forming agents, disinfection bacteriostats, humectants, plasticizers or thickeners, emulsifiers, preservatives, other auxiliaries, solvents and other components, is inevitably introduced from the viewpoint of cost and availability, and is often caused by poor skin feel and occasional anaphylactic reaction due to complex components, so that the phenomena of long healing period, relatively obvious scars after healing and the like are caused.
Disclosure of Invention
The embodiment of the invention aims to provide a liquid dressing and a preparation method thereof, which have the characteristics of natural and safe components and comfortable skin feeling, are simple in preparation method and low in cost, are suitable for industrial application, and are used for solving the problems of complex components, dependence on addition of non-natural components on antibacterial effect and slow wound healing in the related art.
According to a first aspect of embodiments of the present invention, there is provided a liquid dressing, comprising the following components in parts by mass: 0.5-10 parts of glucosamine derivative, 0.1-1 part of porphyridium polysaccharide, 0.01-0.1 part of porphyridium phycobiliprotein and the balance of deionized water, wherein the total amount is 100 parts, and the porphyridium polysaccharide, the porphyridium phycobiliprotein and the glucosamine derivative are obtained from porphyridium phycobiont.
Preferably, the composition comprises the following components in parts by weight: 5 parts of glucosamine, 0.2 part of porphyridium polysaccharide, 0.05 part of porphyridium phycobiliprotein and the balance of deionized water, wherein the total amount is 100 parts.
According to a second aspect of embodiments of the present invention, there is provided a method of manufacturing a liquid dressing, comprising:
(1) obtaining porphyridium polysaccharide, porphyridium phycobiliprotein and glucosamine derivatives (more than 60kDa) from the porphyridium phycobiont;
(2) adding deionized water and 0.5-10 parts of glucosamine derivative into a batching tank, and stirring until the mixture is uniformly mixed;
(3) adding 0.01-0.1 part of phycobiliprotein of porphyridium into the mixed solution obtained in the step (2), and stirring until the solution is uniform;
(4) slowly adding 0.1-1 part of porphyridium polysaccharide into the mixed solution obtained in the step (3), then fixing the volume to 100 parts by using deionized water, and stirring to prepare a mixed solution;
(5) and (4) sterilizing the mixed solution obtained in the step (4) to obtain the liquid dressing.
Preferably, the step of obtaining the porphyridium polysaccharide and the porphyridium phycobiliprotein from the porphyridium algal solution comprises the steps of centrifugation, water washing, ultrafiltration and the like.
Preferably, the glucosamine derivative (> 60kDa) is prepared from porphyridium raw material, chitosan is obtained by degreasing homogenized algae mud, acid/alkali washing and the like, and then the porphyridium-derived glucosamine is obtained by hydrolysis, ethanol precipitation, alcohol washing, reduced pressure rotary evaporation and the like.
Preferably, the composition comprises the following components in parts by weight: 5 parts of glucosamine, 0.2 part of porphyridium polysaccharide, 0.05 part of porphyridium phycobiliprotein and the balance of deionized water, wherein the total amount is 100 parts.
Preferably, in the step (2), the mixing temperature is 30-50 ℃.
Preferably, in the step (2), the stirring speed is 200-300 rpm.
Preferably, in (2), the stirring time is 5 to 30 minutes.
Preferably, in the step (3), the stirring time is 5 to 30 minutes.
Preferably, in the step (4), the stirring time is 5 to 30 minutes.
Preferably, (5) the sterilization mode is as follows:
heating the mixed solution obtained in the step (4) to 95-100 ℃ in a water bath, maintaining the temperature for 10-30 minutes, and sterilizing.
Preferably, (5) is followed by:
(6) and cooling to room temperature, and subpackaging the liquid dressing under aseptic condition to obtain a finished product. Compared with the prior art, the preparation method is simple and efficient, the raw materials for preparing the liquid dressing are all from porphyridium which can be cultured in a large scale, the components are natural and safe, and the porphyridium polysaccharide not only has biological activities of bacteriostasis, antivirus and the like, but also has excellent moisturizing and antioxidant performances. The glucosamine derivative is mainly used as a film forming agent, has high film forming speed, strong adhesion with the surface of the skin after film forming, high transparency of the film, convenient observation of wound surfaces, excellent moisture retention, flexibility and air permeability, can maintain a wet healing environment, effectively blocks bacterial infection, forms good bacteriostasis and healing promotion effects, and avoids protuberant scars caused by abnormal hyperplasia of wound tissues. The phycobiliprotein of porphyridium is used as photosynthetic pigment protein, has multiple performances of radiation resistance, oxidation resistance and the like, and has obvious improvement effect on aspects of skin pigmentation after wound healing and the like. In conclusion, the liquid dressing has excellent performance and good development potential, and is suitable for industrial application.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the application.
Detailed Description
The technical solutions of the present invention will be described clearly and completely with reference to the following embodiments of the present invention, and it should be understood that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example one
A liquid dressing comprises the following components in parts by weight: 5 parts of porphyridium-derived glucosamine derivatives, 0.2 part of porphyridium polysaccharide, 0.05 part of porphyridium phycobiliprotein and the balance of deionized water, wherein the total amount is 100 parts.
The preparation method comprises the following steps:
(1) the steps of obtaining the porphyridium polysaccharide and the water-soluble porphyridium phycobiliprotein from the porphyridium phycoliquid comprise the steps of centrifugation, water washing, ultrafiltration and the like. The glucosamine derivative (more than 60kDa) is prepared from porphyridium raw material, chitosan is obtained by degreasing homogenized algae mud, acid/alkali washing and other steps, and then porphyridium-derived glucosamine is obtained by hydrolysis, ethanol precipitation, alcohol washing, reduced pressure rotary evaporation and other steps.
(2) Adding deionized water into a batching tank, then adding 5 parts of glucosamine derivative into the batching tank, stirring at 30 ℃ and 300rpm for 20 minutes, and uniformly mixing;
(3) adding 0.05 part of phycobiliprotein of porphyridium into the mixed solution obtained in the step (2), and continuing stirring for 20 minutes until the solution is uniform;
(4) slowly adding 0.2 part of porphyridium polysaccharide into the mixed solution obtained in the step (3), and then adding deionized water to the volume of 100 parts. Continuously stirring for 30 minutes to prepare a mixed solution;
(5) heating the mixed solution to 95-100 ℃ in a water bath, maintaining for 15 minutes, and sterilizing;
(6) and cooling to room temperature, and subpackaging the liquid dressing under aseptic condition to obtain a finished product.
Example two
A liquid dressing comprises the following components in parts by weight: 0.5 portion of glucosamine derivative, 0.1 portion of porphyridium polysaccharide, 0.01 portion of porphyridium phycobiliprotein and the balance of deionized water, and the total amount is 100 portions.
The preparation method comprises the following steps:
(1) the porphyridium polysaccharide, the water-soluble porphyridium phycobiliprotein and the glucosamine derivative (> 60kDa) are obtained by separating and purifying the porphyridium liquid, the steps are the same as the first embodiment, and the steps are briefly described here.
(2) Adding deionized water into a batching tank, then adding 0.5 part of glucosamine derivative into the batching tank, stirring for 20 minutes at 30 ℃ and 300rpm, and uniformly mixing;
(3) adding 0.01 part of phycobiliprotein of porphyridium into the mixed solution obtained in the step (2), and continuing stirring for 20 minutes until the solution is uniform;
(4) slowly adding 0.1 part of porphyridium polysaccharide into the mixed solution obtained in the step (3), and then adding deionized water to the volume of 100 parts. Continuously stirring for 30 minutes to prepare a mixed solution;
(5) heating the mixed solution to 95-100 ℃ in a water bath, maintaining for 15 minutes, and sterilizing;
(6) and cooling to room temperature, and subpackaging the liquid dressing under aseptic condition to obtain a finished product.
EXAMPLE III
A liquid dressing comprises the following components in parts by weight: 10 parts of glucosamine derivative, 1 part of porphyridium polysaccharide, 0.1 part of porphyridium phycobiliprotein and the balance of deionized water, wherein the total amount is 100 parts.
The preparation method comprises the following steps:
(1) the porphyridium polysaccharide, the water-soluble porphyridium phycobiliprotein and the glucosamine derivative (> 60kDa) are obtained by separating and purifying the porphyridium liquid, the steps are the same as the first embodiment, and the steps are briefly described here.
(2) Adding deionized water into a batching tank, then adding 10 parts of glucosamine derivative into the batching tank, stirring at 30 ℃ and 300rpm for 20 minutes, and uniformly mixing;
(3) adding 0.1 part of phycobiliprotein of porphyridium into the mixed solution obtained in the step (2), and continuing stirring for 20 minutes until the solution is uniform;
(4) slowly adding 1 part of porphyridium polysaccharide into the mixed solution obtained in the step (3), and then adding deionized water to the volume of 100 parts. Continuously stirring for 30 minutes to prepare a mixed solution;
(5) heating the mixed solution to 95-100 ℃ in a water bath, maintaining for 15 minutes, and sterilizing;
(6) and cooling to room temperature, and subpackaging the liquid dressing under aseptic condition to obtain a finished product.
Example four
A liquid dressing comprises the following components in parts by weight: the common film-forming agent polyvinyl alcohol is used for replacing glucosamine derivatives, the addition amount is 10 parts, the porphyridium polysaccharide is 0.2 part, the porphyridium phycobiliprotein is 0.05 part, the balance is deionized water, and the total amount is 100 parts.
The preparation method comprises the following steps:
(1) separating and purifying the porphyridium polysaccharide and water-soluble porphyridium phycobiliprotein to obtain porphyridium polysaccharide and water-soluble porphyridium phycobiliprotein;
(2) adding deionized water into a batching tank, then adding 10 parts of polyvinyl alcohol into the batching tank, stirring at 30 ℃ and 300rpm for 20 minutes, and uniformly mixing;
(3) adding 0.05 part of phycobiliprotein of porphyridium into the mixed solution obtained in the step (2), and continuing stirring for 20 minutes until the solution is uniform;
(4) slowly adding 0.2 part of porphyridium polysaccharide into the mixed solution obtained in the step (3), and then adding deionized water to the volume of 100 parts. Continuously stirring for 30 minutes to prepare a mixed solution;
(5) heating the mixed solution to 95-100 ℃ in a water bath, maintaining for 15 minutes, and sterilizing;
(6) and cooling to room temperature, and subpackaging the liquid dressing under aseptic condition to obtain a finished product.
EXAMPLE five
A liquid dressing comprises the following components in parts by weight: 5 portions of glucosamine derivative, no porphyridium polysaccharide, 0.05 portion of porphyridium phycobiliprotein and the balance of deionized water, wherein the total amount is 100 portions. The preparation method comprises the following steps:
(1) separating and purifying the porphyridium algae liquid to obtain water-soluble porphyridium phycobiliprotein and glucosamine derivatives;
(2) adding deionized water into a batching tank, then adding 5 parts of glucosamine derivative into the batching tank, stirring at 30 ℃ and 300rpm for 20 minutes, and uniformly mixing;
(3) and (3) adding 0.05 part of phycobiliprotein of porphyridium into the mixed solution obtained in the step (2), and fixing the volume to 100 parts by using deionized water. Continuously stirring for 30 minutes to prepare a mixed solution;
(4) heating the mixed solution to 95-100 ℃ in a water bath, maintaining for 15 minutes, and sterilizing;
(5) and cooling to room temperature, and subpackaging the liquid dressing under aseptic condition to obtain a finished product.
EXAMPLE six
A liquid dressing comprises the following components in parts by weight: 5 parts of porphyridium-derived glucosamine derivatives, 0.2 part of porphyridium polysaccharide, no porphyridium phycobiliprotein and the balance of deionized water, wherein the total amount is 100 parts.
The preparation method comprises the following steps:
(1) separating and purifying the porphyridium liquid to obtain porphyridium polysaccharide and glucosamine derivatives (greater than 60 kDa);
(2) adding deionized water into a batching tank, then adding 5 parts of glucosamine derivative into the batching tank, stirring at 30 ℃ and 300rpm for 20 minutes, and uniformly mixing;
(3) slowly adding 0.2 part of porphyridium polysaccharide into the mixed solution obtained in the step (2), then fixing the volume to 100 parts by using deionized water, and continuously stirring for 30 minutes to prepare a mixed solution;
(4) heating the mixed solution to 95-100 ℃ in a water bath, maintaining for 15 minutes, and sterilizing;
(5) and cooling to room temperature, and subpackaging the liquid dressing under aseptic condition to obtain a finished product.
Comparative example 1
Preparing a liquid dressing according to the composition of a conventional liquid auxiliary material, wherein the liquid dressing comprises the following components in parts by weight: 10 parts of polyvinyl alcohol, 2 parts of glycerol, 0.5 part of phenoxyethanol, 0.5 part of ethyl p-hydroxybenzoate and the balance of deionized water, wherein the total amount is 100 parts. The preparation method comprises the following steps: weighing polyvinyl alcohol, glycerol, phenoxyethanol and ethyl p-hydroxybenzoate according to the parts by weight, sequentially dissolving the polyvinyl alcohol, the glycerol, the phenoxyethanol and the ethyl p-hydroxybenzoate in deionized water, fixing the volume to 100 parts, and then sterilizing for 30 minutes by using ultraviolet.
To verify the practical application effect of the present invention, the following experimental evaluation was carried out.
1. Evaluation of physical, chemical and safety
The pH, the heavy metal and the initial content of the mixed bacteria are respectively detected according to a pH measuring method of the fourth 0631 of the 'Chinese pharmacopoeia' 2015 edition, a detection method of a heavy metal checking method of the Chinese pharmacopoeia 2015 edition 0821 and an appendix C of GB/T15980. The results show that the pH range of the liquid dressing samples in the embodiments 1-6 is 5.5-7.5, the heavy metal content of the dressing is less than or equal to 20 mu g/g, the initial contamination bacteria number of the dressing is less than or equal to 50cfu/g, and the physicochemical indexes meet relevant regulations.
According to GB/T16886.5-2017 part 5 of medical device biology evaluation: in vitro cytotoxicity test method the in vitro cytotoxicity of the liquid dressings obtained in examples 1 to 6 and the comparative example was tested; according to GB/T16886.10-2017 part 10 of medical device biology evaluation: the skin irritation of the liquid dressings obtained in examples 1 to 6 and comparative examples was tested by the irritation and delayed type hypersensitivity test method; according to GB/T16886.10-2017 part 10 of medical device biology evaluation: irritation and skin sensitization test method the liquid dressings obtained in examples 1 to 6 and comparative example were tested for skin sensitization. The test results are shown in table 1.
TABLE 1 safety evaluation index and results
The results of animal skin irritation tests, skin sensitization tests and in-vitro cytotoxicity tests respectively carried out on the liquid dressings in the embodiments 1 to 6 show that the liquid dressings are safe and nontoxic.
2. Evaluation of bacteriostatic Properties
The bacteriostatic activity of the liquid dressings obtained in examples 1 to 6 and the comparative example was tested, and the test method was: respectively taking 100 μ L of 1 × 108cfu/mL of escherichia coli liquid, staphylococcus aureus liquid, bacillus subtilis liquid and pyocyaneaThe bacillus liquid is coated on LB plate respectively, after the liquid is absorbed by the culture medium in the plate, a hole (diameter 5.80mm) is punched on the culture medium, 50 mu L of liquid dressing is dripped into the hole, and the plate is cultured for 36h at 37 ℃. The radius of the bacteriostatic ring (the bacteriostatic ability can be determined when the radius of the bacteriostatic ring is more than 5.80mm) is observed and measured, and the measurement results are shown in table 2.
TABLE 2 evaluation of bacteriostatic properties of liquid dressing samples
As can be seen from the table above, the liquid dressing prepared by the invention has certain inhibition effect on escherichia coli, staphylococcus aureus, bacillus subtilis and pseudomonas aeruginosa, and especially has obvious inhibition effect on staphylococcus aureus. The comparison results of the examples 1, 2, 3 and 5 show that the main component with the antibacterial effect in the liquid dressing is the porphyridium polysaccharide, the antibacterial effect of the porphyridium phycobiliprotein is slightly weak, the antibacterial rate can be reduced by reducing the content of the porphyridium polysaccharide, and the antibacterial activity of the product can be improved by increasing the content of the components. Meanwhile, after the data in the table are analyzed, the functions of the single components have complementarity, and the mixture ratio in the embodiment 1 does not have the highest bacteriostatic efficiency, but comprehensively considers the cost and the effect, and is still the preferable composition ratio. The liquid dressing prepared conventionally contains antiseptic bacteriostats (phenoxyethanol and ethyl p-hydroxybenzoate) and therefore has certain bacteriostasis, but the bacteriostasis effect is still poorer than that of the liquid dressing prepared in the embodiment under the concentration used in the comparative example. The liquid dressing has the obvious advantages of being natural and bacteriostatic, and can reduce the use of other ingredients such as preservatives and the like.
3. Evaluation of wound healing-promoting effectiveness
The ability of promoting healing of the liquid dressing is evaluated by utilizing an animal experiment, 18 male SD rats are selected and divided into 9 groups, and the group numbers are respectively as follows: 1-6 groups, 1-3 control groups, and single cage feeding of experimental rats. Carrying out intraperitoneal injection anesthesia by using 5% chloral hydrate according to the dose of 6ml/kg, then removing hairs on the chest section of each group of backs, scratching a 2cm wound on the exposed skin surface, scratching the wound under the real cortex to seep blood from the wound, immediately coating the liquid dressings prepared in the examples 1-6 on 1-6 groups respectively, coating the liquid dressing prepared in the comparative example 1 on the control group 1, and covering the liquid dressing with gauze. Control 2 was attached to a commercially available ordinary wound dressing and control 3 was covered with only ordinary sterile gauze. The liquid dressing, the wound paste or the sterile gauze are replaced once a day, the liquid dressing is directly sprayed after the wound surface does not bleed, the gauze is not required to be covered, and the red and swollen, scabbing and scabbing conditions of the wound surface in the days 2, 4, 6 and 8 are observed and recorded every day. The results of the experiment are shown in table 3.
Table 3 verification of healing promoting ability of liquid dressing
By observing and analyzing the healing conditions of the wounds among different groups, the results show that: the liquid dressing has the effect of promoting wound healing, accelerates scar formation and scar removal, simultaneously has no obvious skin scar after healing, and shows that the healing effect is better. The conventional wound plaster and the sterile gauze group have obvious scars, and particularly, the common gauze group has obvious slight infection signs in the first 4 days, so that the wound healing period is prolonged, and scars are particularly obvious after healing. In example 2, the content of the components was reduced, so that the film forming effect was poor, and the scabbing time were delayed. Examples 4-6 reduction of any of the three main components described above all resulted in a reduction in the effectiveness of the liquid dressing of the present invention, although it still had the ability to promote wound healing compared to the control group. In conclusion, the liquid dressings prepared in examples 1 and 3 have similar wound healing promoting functions, indicating that the intended use effect can be obtained as long as the content of the functional main ingredient is an appropriate value.
It should be emphasized that the above-described embodiments are merely illustrative of the present invention, which is not to be considered limiting, and that those skilled in the art, after reading this specification, may make modifications to the embodiments as required, without any inventive contribution, but within the scope of the appended claims.
Claims (10)
1. The porphyridium-based liquid dressing is characterized by comprising the following components in parts by mass: 0.5-10 parts of glucosamine derivative, 0.1-1 part of porphyridium polysaccharide, 0.01-0.1 part of porphyridium phycobiliprotein and the balance of deionized water, wherein the total amount is 100 parts, and the porphyridium polysaccharide, the porphyridium phycobiliprotein and the glucosamine derivative are obtained from porphyridium phycobiont.
2. The liquid dressing of claim 1, which is characterized by comprising the following components in parts by mass: 5 parts of glucosamine, 0.2 part of porphyridium polysaccharide, 0.05 part of porphyridium phycobiliprotein and the balance of deionized water, wherein the total amount is 100 parts.
3. A method of making a liquid dressing, comprising:
(1) obtaining porphyridium polysaccharide, porphyridium phycobiliprotein and glucosamine derivatives from the porphyridium phycobiont;
(2) adding deionized water and 0.5-10 parts of glucosamine derivative into a batching tank, and stirring until the mixture is uniformly mixed;
(3) adding 0.01-0.1 part of phycobiliprotein of porphyridium into the mixed solution obtained in the step (2), and stirring until the solution is uniform;
(4) slowly adding 0.1-1 part of porphyridium polysaccharide into the mixed solution obtained in the step (3), then fixing the volume to 100 parts by using deionized water, and stirring to prepare a mixed solution;
(5) and (4) sterilizing the mixed solution obtained in the step (4) to obtain the liquid dressing.
4. The method for preparing a liquid dressing according to claim 3, wherein in the step (2), the mixing temperature is 30-50 ℃.
5. The method for preparing a liquid dressing according to claim 3, wherein in (2), the stirring speed is 200-300 rpm.
6. The method for preparing a liquid dressing according to claim 3, wherein in (2), the stirring time is 5 to 30 minutes.
7. The method for preparing a liquid dressing according to claim 3, wherein in (3), the stirring time is 5-30 minutes.
8. The method for preparing a liquid dressing according to claim 3, wherein in the step (4), the stirring time is 5-30 minutes.
9. The method for preparing a liquid dressing according to claim 3, wherein in (5), the sterilization mode is as follows:
heating the mixed solution obtained in the step (4) to 95-100 ℃ in a water bath, maintaining the temperature for 10-30 minutes, and sterilizing.
10. The method for preparing a liquid dressing according to claim 3, wherein the step (5) further comprises:
(6) and cooling to room temperature, and subpackaging the liquid dressing under aseptic condition to obtain a finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111580252.2A CN114225100A (en) | 2021-12-22 | 2021-12-22 | Porphyridium-based liquid dressing and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111580252.2A CN114225100A (en) | 2021-12-22 | 2021-12-22 | Porphyridium-based liquid dressing and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114225100A true CN114225100A (en) | 2022-03-25 |
Family
ID=80761204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111580252.2A Pending CN114225100A (en) | 2021-12-22 | 2021-12-22 | Porphyridium-based liquid dressing and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114225100A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115920001A (en) * | 2022-07-28 | 2023-04-07 | 广东医科大学 | Composition containing porphyridium polypeptide, preparation method and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09308680A (en) * | 1996-05-21 | 1997-12-02 | Micro Arujie Corp Kk | Antimicrobial sheet having biodecomposability and its production |
| US20180207079A1 (en) * | 2015-07-21 | 2018-07-26 | Greenaltech, S.L. | Compositions for protecting skin comprising dna repair enzymes and phycobiliprotein |
| CN110559475A (en) * | 2019-09-19 | 2019-12-13 | 广州博民生物科技有限公司 | Compound liquid dressing and preparation method thereof |
| CN111569044A (en) * | 2020-05-31 | 2020-08-25 | 广东湛江海洋医药研究院 | Composition containing porphyridium polypeptide and preparation method thereof |
| CN113278091A (en) * | 2021-06-29 | 2021-08-20 | 广东湛江海洋医药研究院 | Porphyridium polysaccharide and preparation method and application thereof |
| CN113476891A (en) * | 2021-08-06 | 2021-10-08 | 中国科学院南海海洋研究所 | Method for simultaneously extracting multiple active substances from porphyridium |
-
2021
- 2021-12-22 CN CN202111580252.2A patent/CN114225100A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09308680A (en) * | 1996-05-21 | 1997-12-02 | Micro Arujie Corp Kk | Antimicrobial sheet having biodecomposability and its production |
| US20180207079A1 (en) * | 2015-07-21 | 2018-07-26 | Greenaltech, S.L. | Compositions for protecting skin comprising dna repair enzymes and phycobiliprotein |
| CN110559475A (en) * | 2019-09-19 | 2019-12-13 | 广州博民生物科技有限公司 | Compound liquid dressing and preparation method thereof |
| CN111569044A (en) * | 2020-05-31 | 2020-08-25 | 广东湛江海洋医药研究院 | Composition containing porphyridium polypeptide and preparation method thereof |
| CN113278091A (en) * | 2021-06-29 | 2021-08-20 | 广东湛江海洋医药研究院 | Porphyridium polysaccharide and preparation method and application thereof |
| CN113476891A (en) * | 2021-08-06 | 2021-10-08 | 中国科学院南海海洋研究所 | Method for simultaneously extracting multiple active substances from porphyridium |
Non-Patent Citations (2)
| Title |
|---|
| 陈晓清: "《二种微藻多糖和蛋白质的纯化及部分生物活性研究》", 《中国优秀硕士学位论文数据库》 * |
| 陈晓清等: "二种微藻多糖与蛋白质提取物的抗菌活性", 《福建师范大学学报(自然科学版)》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115920001A (en) * | 2022-07-28 | 2023-04-07 | 广东医科大学 | Composition containing porphyridium polypeptide, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111632075B (en) | Exosome preparation for promoting skin wound healing and preparation method thereof | |
| CN107185031B (en) | A kind of biologically active medical dressing and preparation method thereof | |
| CN104258456B (en) | A kind of wound repair gel containing hexagonal mesoporous silicon and preparation method thereof | |
| D'souza et al. | Basella alba stem extract integrated poly (vinyl alcohol)/chitosan composite films: A promising bio-material for wound healing | |
| CN111529478A (en) | Moisturizing hand-washing-free disinfectant and preparation method thereof | |
| CN108354880A (en) | A kind of baby child's skin care compositions and methods | |
| CN109010124B (en) | Marine refined gynecological antibacterial gel and preparation method thereof | |
| CN110859989B (en) | Liquid band-aid and preparation method thereof | |
| JPH05506861A (en) | Compositions and methods for topical treatment of damaged or diseased tissue | |
| CN114767708B (en) | Stable gynecological antibacterial composition and gynecological care solution | |
| CN114225100A (en) | Porphyridium-based liquid dressing and preparation method thereof | |
| CN105169455A (en) | A kind of external emergency medical dressing for burns and scalds and preparation method thereof | |
| CN108578279B (en) | Application of skin care composition | |
| CN112891615B (en) | Liquid adhesive bandage and preparation method thereof | |
| CN111012945B (en) | A kind of waterproof traditional Chinese medicine liquid band-aid and preparation method thereof | |
| CN109224124B (en) | Liquid dressing for stopping bleeding and promoting healing | |
| US11058712B2 (en) | Film for topical application in the treatment of skin lesions and method of obtaining and applying same | |
| CN113855849A (en) | Dressing composition and preparation method and application thereof | |
| CN106729962B (en) | Skin antibacterial protective film liquid and preparation method thereof | |
| CN111012944A (en) | Liquid dressing based on alginate and hyaluronic acid and preparation method thereof | |
| CN107595819B (en) | A kind of Nano diamond modified liquid adhesive bandage and preparation method thereof | |
| CN115770209A (en) | Rod-shaped lithospermum ointment containing three-purple oil and preparation method thereof | |
| CN111084902B (en) | Liquid dressing and preparation method thereof | |
| CN107982300B (en) | Spray and preparation method and application thereof | |
| CN116271205B (en) | Liquid band-aid containing black phosphorus nano sheet component and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |